Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

NCT: NCT06810518 · RECRUITING

NCT IDNCT06810518
StatusRECRUITING
Start Date2025-03-25
Completion2026-12-31

Brief Summary

The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture. The goal of the study is to generate data to support positive and negative predictive value of the ALPCO Calprotectin assay in patients with signs and symptoms of IBS or IBD.

Frequently Asked Questions

What is ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool?

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool is a clinical trial registered under NCT06810518. Current status: RECRUITING.

What is the status of NCT06810518?

The current status of NCT06810518 (ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool) is: RECRUITING.

When did ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool start?

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool started on 2025-03-25.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.